Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer - Molecular Cancer Triple negative breast cancer (TNBC) is a heterogeneous group of tumors which lack estrogen receptor, progesterone receptor, and HER2 expression. Targeted therapies have limited success in treating TN...

1/2 Nataly Kravchenko-Balasha speaks to patient-specific approaches to identify steady-state dynamics and disease-deviation from that steady state. #ICSB2024 #systemsOncology #SystemsBiology doi.org/10.1186/s129...

Day 2 of # ICSB2024 opened by Thomas Hofer examining the cancer clock - the time taken between acquisition of a founder mutation and emergence of the cancer, and the role of convergent evolution of subsequent tumourogenic mutations #SystemsOncology 1/2

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of oesophageal cancer CDKN2A is a tumour suppressor located in chromosome 9p21 and frequently lost in Barrett’s oesophagus (BO) and oesophageal adenocarcinoma (OAC). How CDKN2A and other 9p21 gene co-deletions affect OAC e...

5/5 @ciccarellilab.bsky.social shows that tumour suppressor genes such as CDKN2A can select against P53 loss. Context of loss of CDKN2A determines cancer evolution and prognosis @biorxivpreprint.bsky.social www.biorxiv.org/content/10.1... #ICSB2024 #SystemsOncology

Redirecting

4/5 Tumour suppressor genes are (more commonly?) mutated in somatic precancerous cells than the cancer. Reviewed @cellpress.bsky.social doi.org/10.1016/j.cc... #ICSB2024 #SystemsOncology

Mechanistic insights into the interactions between cancer drivers and the tumour immune microenvironment - Genome Medicine Background The crosstalk between cancer and the tumour immune microenvironment (TIME) has attracted significant interest in the latest years because of its impact on cancer evolution and response to t...

3/5 @ciccarellilab.bsky.social is interested in the transition between driver mutation in a somatic cell, and probabilistic transition to cancer. genomemedicine.biomedcentral.com/articles/10.... #ICSB2024 #SystemsOncology

Pan-cancer detection of driver genes at the single-patient resolution - Genome Medicine Background Identifying the complete repertoire of genes that drive cancer in individual patients is crucial for precision oncology. Most established methods identify driver genes that are recurrently ...

2/5 A cancer driver by definition must sit in a fragile part of the biological system, eg at a hub of protein interactions. Ciccarelli developed a systems scale score to predict new driver genes genomemedicine.biomedcentral.com/articles/10.... #ICSB2024 #SystemsOncology

Hi there👋! We’re the Systems Medicine of Tumor Microenvironment Lab. Our passion? Exploring the #TME through #SystemsOncology. Harnessing the power of our diverse and multidisciplinary team, we use innovative approaches to uncover #Biomarkers and transform these insights into clinical applications.